Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) and Insmed (NASDAQ:INSM – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.
Insider & Institutional Ownership
40.1% of Palvella Therapeutics shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Palvella Therapeutics and Insmed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palvella Therapeutics | N/A | -47.84% | -38.33% |
| Insmed | -76.94% | -123.94% | -44.30% |
Volatility and Risk
Analyst Recommendations
This is a summary of recent ratings and target prices for Palvella Therapeutics and Insmed, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palvella Therapeutics | 1 | 0 | 12 | 2 | 3.00 |
| Insmed | 1 | 0 | 22 | 2 | 3.00 |
Palvella Therapeutics presently has a consensus price target of $209.14, indicating a potential upside of 38.30%. Insmed has a consensus price target of $204.91, indicating a potential upside of 70.87%. Given Insmed’s higher possible upside, analysts clearly believe Insmed is more favorable than Palvella Therapeutics.
Earnings and Valuation
This table compares Palvella Therapeutics and Insmed”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Palvella Therapeutics | $42.81 million | 50.90 | -$41.72 million | ($4.83) | -31.31 |
| Insmed | $606.42 million | 43.18 | -$1.28 billion | ($4.11) | -29.18 |
Palvella Therapeutics has higher earnings, but lower revenue than Insmed. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.
Summary
Palvella Therapeutics beats Insmed on 7 of the 13 factors compared between the two stocks.
About Palvella Therapeutics
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
